Single-dose CM383 in healthy adult men
Official title: A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of CM383 Following Intravenous and Subcutaneous Administration in Healthy Adult Subjects
Run by Keymed Biosciences Co.Ltd · NCT07292688 · Data updated 2026-11-12
This trial will test a single dose of CM383 given by IV infusion or subcutaneous injection in healthy adult men to see how the drug is processed, whether it triggers immune responses, and if it is safe.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 54 Years |
| Sex | Men only |
| Enrollment | 30 (estimated) |
| Sponsor | Keymed Biosciences Co.Ltd Industry-sponsored |
| Locations | 1 site (Hangzhou) |
| Status | Recruiting |
| Started | January 2026 |
| Main results expected | July 2026 |
| Study ends | July 2026 |
| Registry record updated | January 23, 2026 |
| Trial ID | NCT07292688 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy men aged 18–54 who can give informed consent, comply with study procedures, and have no recent heavy alcohol or tobacco use, drug abuse, major surgery, or allergies to similar biologics.
✕Probably not a fit
People with active medical conditions, women, heavy smokers or drinkers, recent drug users, or those with known allergies to monoclonal antibody drugs are unlikely to receive benefit from participating.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 1, single-center, randomized, open-label, parallel-controlled study in healthy male volunteers. Participants aged 18–54 receive a single dose of CM383 either by intravenous infusion or by subcutaneous injection, with serial sampling to measure pharmacokinetics, pharmacodynamics, and immunogenicity. Safety and tolerability are monitored through adverse event reporting, vital signs, and laboratory testing during follow-up visits. Results will guide dose selection, preferred administration route, and safety monitoring for later clinical studies.
Why it matters
Potential benefit: If successful, the study could identify a safe dose and the best way to give CM383 to inform later-stage testing.
How similar studies have gone: Single-dose PK/PD and safety studies in healthy volunteers are routine for biologic therapies, and comparable monoclonal antibodies have often shown predictable pharmacokinetics and manageable safety in Phase I.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects age ≥ 18 years \& ≤54 years. * Subjects voluntarily signed the Informed Consent Form and were able to comply with the provisions of this protocol. Exclusion Criteria: * The average number of cigarettes smoked per day is greater than 5 within 3 months prior to screening. * Drinking heavily within 3 months prior to screening, or unable to guarantee not to drink alcohol during the research period, or positive alcohol breath testing. * History of drug abuse within 1 year prior to screening, or positive urine drug abuse screening. * Blood donation or any other form of blood loss exceeding 400 mL, or accepting blood transfusion within 12 weeks prior to screening. * Suspected allergy to Aβ-antibody drugs, humanized monoclonal antibody drugs and their excipients, or other biological agents, or have a history of severe allergic reactions to other drugs. * Severe trauma or undergo major surgery within 6 months prior to screening, or planned surgery during the research period.
Where it's running
-
The Second Affiliated Hospital Zhejiang University School of Medcine
Hangzhou, China Recruiting
Study contacts
- Principal investigator: Bo Jiang — Second Affiliated Hospital, Zhejiang University, School of Medicine
- Study coordinator: Qian Jia
- Email: qianjia@keymedbio.com
- Phone: 028-88610620
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Long-term safety and efficacy of CM512 for atopic dermatitis
This open-label follow-up will test whether continuing CM512 is safe and helps people with atopic dermatitis who finished a parent CM512 study.
-
Single intravenous CM559 dosing in healthy adult men
This trial tests single intravenous doses of CM559 to see if they are safe and how the drug is processed in healthy men aged 18–60.
-
CM336 treatment for relapsed or refractory autoimmune cytopenia
This trial will test whether CM336, a BCMA/CD3 bispecific antibody given by injection, can help adults with relapsed or refractory autoimmune cytopenias such as ITP, AIHA, or Evans syndrome.
-
CM512 injection for adults with chronic spontaneous urticaria
This study will test whether injections of CM512 reduce hives and itching in adults with chronic spontaneous urticaria who still have symptoms despite second-generation H1‑antihistamines.
-
CM336 (BCMA/CD3 bispecific antibody) for adults with relapsed or refractory light-chain (AL) amyloidosis
This will test whether CM336, a BCMA/CD3 bispecific antibody, helps adults with relapsed or refractory AL amyloidosis and is safe to use.
-
CM518D1 treatment for advanced solid tumors
This trial will test CM518D1 to see if it is safe, tolerable, and can help adults with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.